Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — FY2022 Earnings Presentation
26 slides from Arecor Therapeutics's earnings presentation, April 2023
Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Results for the year ended 31 December 2022 April 2023 www.arecor.com
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Presentation Team
Presentation Team Dr Sarah Howell Susan Lowther Chief Executive Officer Chief Financial Officer Page 2 Arecor 2023 | Confidential
Slide 4: Focused on transforming patient care by enhancing existing therapeutic medicines
We are focused on transforming patient care by enhancing existing therapeutic medicines to bring safer, more effective and convenient treatments to patients Page 3 Arecor 2023 | Confidential
Slide 5: Company summary
Company summary Driving better healthcare through the transformation of today’s therapies Arestat™ proprietary technology Clinical company developing proprietary platform pipeline of enhanced medicines Vision to build a • Enhances properties of existing • Diabetes - favourable clinical data & near-
Slide 6: Operational Highlights (including post-period events)
Operational Highlights (including post-period events) Driving better healthcare through the transformation of today’s therapies Proprietary pipeline • Second Phase I trial of AT278 underway in people with type 2 diabetes • Positive results from US Phase I clinical trial of AT247 delivered via insuli
Slide 7: A broad portfolio of de-risked development and commercial products
A broad portfolio of de-risked development and commercial products Balanced portfolio of commercial and development assets offering optionality on partnering and revenue growth potential Current Product Area Research Preclinical Phase I Phase II Phase III Est launch market size AT278 Diabetes 2025 A
Slide 8: Capturing long-term value through partnerships
Capturing long-term value through partnerships Specialty Hospital RTU products • Growing portfolio demonstrates potential of Arestat™ for partners AT307 transferred to Hikma for further development and commercialisation Increasing portfolio of technology partnerships Eight new partnerships since IPO
Slide 9: Best-in-class insulins for more effective treatment of diabetes
01 Best-in-class insulins for more effective treatment of diabetes Page 8 Arecor 2023 | Confidential
Slide 10: Diabetes in crisis: There is still a need for improved insulins
Diabetes in crisis: There is still a need for improved insulins A major worldwide health issue with significant unmet needs in diabetes care 537 million adults are living with diabetes $966 billion 6.7 million estimated global deaths due to diabetes expenditure in 2021 Page 9 Arecor 2023 | Confident
Slide 11: Diabetes: Portfolio of best-in-class ultra-rapid and concentrated insulins
Diabetes: Portfolio of best-in-class ultra-rapid and concentrated insulins A major worldwide health issue with significant unmet needs in diabetes care AT278 ‘disruptor insulin’ the first ultra- concentrated ultra-rapid acting insulin for Arecor’s goal is to improve treatment of type 2 diabetes trea
Slide 12: AT278: An ultra-concentrated, ultra-rapid acting insulin candidate
02 AT278 An ultra-concentrated, ultra-rapid acting insulin candidate Page 11 Arecor 2023 | Confidential
Slide 13: AT278 500 U/mL: Creating a disruptor insulin
AT278 500 U/mL: Creating a disruptor insulin Potential to be the first concentrated ultra-rapid insulin (URI) product available to patients The need AT278 potential to be first and • Growing number of type 2 diabetics requiring high daily doses of insulin (>100U/day) only ultra-concentrated rapid ac
Slide 14: Why switch to an ultra-concentrated, ultra-rapid acting insulin?
Why switch to an ultra-concentrated, ultra-rapid acting insulin? Currently no rapid acting insulin (RAI) on the market with a concentration >200U/mL Concentrated insulins growth market up to ~$1B existing market • Concentrated insulin reduces injection volumes and potentially fewer injections/day •
Slide 15: AT278 500 U/mL: Positive results from first Phase I clinical study
AT278 500 U/mL: Positive results from first Phase I clinical study; significantly accelerated PK/PD compared to 100 U/mL NovoRapid® 1st Phase I clinical study¹ successfully met all primary endpoints with best-in-class profile Successfully met all primary endpoints with best-in-class profile 1Double-
Slide 16: AT278 Second clinical trial initiated in January 2023
AT278 Second clinical trial initiated in January 2023 Potential to become gold standard insulin for people with diabetes with high daily insulin needs • Initiated January 2023, first patient dosed March 2023, results expected Q4 23 • Phase I randomised, double-blind study in 28 adult patients with t
Slide 17: AT247: An ultra-rapid acting insulin candidate
03 AT247 An ultra-rapid acting insulin candidate Page 16 Arecor 2023 | Confidential
Slide 18: AT247 Potential to enable transformational fully closed loop artificial pancreas
AT247 Potential to enable transformational fully closed loop artificial pancreas Improve quality and life and outcomes for Type 1 diabetic patients CGM Measures blood AT247 best-in-class PK/PD glucose levels in demonstrated in Phase I real-time clinical study AP ‘holy grail’ for people living with T
Slide 19: Successful completion of two clinical trials investigating potential of AT247
Successful completion of two clinical trials investigating potential of AT247 Support AT247 potential to enable fully closed loop artificial pancreas for people with Type 1 diabetes First in human, single-dose Phase I trial (2020) Three-day insulin pump Phase I trial (2022) • Demonstrated a signific
Slide 20: Tetris Pharma
04 Tetris Pharma Page 19 Arecor 2023 | Confidential
Slide 21: Tetris Pharma and European roll-out of Ogluo
Tetris Pharma and European roll-out of Ogluo® Key diabetes product Ogluo® • Integration of Tetris Pharma team Ready-to-use glucagon for • European commercial roll out continuing following emergency use to treat severe earlier UK launch hypoglycemia in people with diabetes • Product available to pati
Slide 22: Financials and newsflow
04 Financials and newsflow Page 21 Arecor 2023 | Confidential
Slide 23: 2022 Financial Highlights
2022 Financial Highlights Doubling of total income Key financials Revenue base • Total Income of £3.5 million (2021: £1.8 million) expanding to product • Investment in R&D of £8.6 million (2021: £5.4 million) sales, licenses, • Loss after tax for the year of £9.3 million (2021: £6.2 million) milesto
Slide 24: Key Financials
Key Financials Broadening the revenue mix as a platform for future growth £m FY 2022 FY 2021 Doubling of total income to £3.5m Formulation development 1.4 1.2 • New formulation development projects Product sales 1.0 - • Five months of Tetris Pharma Total revenue 2.4 1.2 • Full year Innovate grant •
Slide 25: Significant upcoming milestones to drive growth
Significant upcoming milestones to drive growth Existing licensing and new licensing upside potential A significant self-sustaining biopharmaceutical company 2022 2023 2024 onwards • AT247-103 clinical results • HIK achieve next license milestone • Significant potential returns from license • Initia
Slide 26: Thank you
Contact Sarah Howell, CEO sarah.howell@arecor.com Susan Lowther, CFO susan.lowther@arecor.com Thank you www.arecor.com